Assessment of chromatin remodeling of acute myeloid leukemia cells treated with gilteritinib

Gilteritinib is a FLT3 inhibitor that has been approved for relapsed acute myeloid leukemia (AML) carrying FLT3 mutations. However, the effects of this drug on chromatin remodeling of AML cells remains unknown. We tested the state of chromatin openness of AML cells obtained from a patient before and after treatment with gilteritinib using Assay for Transposase-Accessible Chromatin with high-throughput sequencing (ATAC-seq). Assay for Transposase-Accessible Chromatin with high-throughput sequencing (ATAC-seq) for 2 AML cell samples: before and after.